ALPHARETTA, Ga., May 1, 2024 /PRNewswire/ -- MagVenture is proud
to announce its partnership with Magnus Medical, providing its
industry-leading MagPro® magnetic stimulation system to
support an exciting new chapter in therapeutic transcranial
magnetic stimulation (TMS) through Magnus'
SAINT® neuromodulation system.
SAINT therapy will enable patients to receive a quick, highly
effective treatment for Major Depressive Disorder (MDD), especially
in the acute setting where TMS has been limited in adoption.
SAINT therapy is an FDA-cleared, rapid-acting, and
non-invasive treatment for treatment-resistant major depression in
adults who have failed to achieve satisfactory improvement from
prior antidepressant medications. Treatment consists of
MRI-guided identification of stimulation targets and a proprietary
protocol that condenses treatment to just five days.
"MagVenture's high-performance intermittent theta burst system
supports our innovative SAINT therapy, therefore, we are poised to
deliver rapid and effective relief to people who suffer from
treatment-resistant depression," said Christian Gormsen, President and CEO of Magnus
Medical. "This collaboration underscores our commitment to
advancing the treatment of neuropsychiatric disorders and changing
people's lives."
Kerry Rome, SVP of Sales and
Marketing at MagVenture, Inc. continued, "We are excited to enable
the expansion of SAINT across the U.S. powered by MagVenture
hardware, as well as installation and service support to ensure
customers who offer SAINT will experience the same
high-quality and reliable operations for which MagVenture is
known."
MagVenture and Magnus Medical will exhibit at the upcoming
Clinical TMS Society Annual Meeting in London in June where the SAINT system can be
seen firsthand.
About MagVenture
MagVenture is a private, market-leading manufacturer of
non-invasive TMS systems worldwide. Headquartered in Denmark, MagVenture has been pioneering
leading-edge TMS solutions for more than 30 years. MagVenture's
systems are used for both research and treatment in the fields of
psychiatry, neurophysiology, neurology, cognitive neuroscience, and
rehabilitation. For more information, visit www.magventure.com
Media inquiries:
Kerry Rome kr@magventure.com or
Lauren Schultheiss
ls@magventure.com, MagVenture, Inc., +1.888.624.7764
Logo -
https://mma.prnewswire.com/media/2402306/Logo_2700_px_wide_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/magventure-announces-collaboration-with-magnus-medical-to-bring-the-saint-neuromodulation-system-to-market-302132585.html